European guidelines for breast cancer treatment

Aromatase gene amplification

Breast conservation therapy

Improving care for cancer patients

Managing cancer and living meaningfully

Treating the patient, not the disease: in memory of Umberto Veronesi

Clinical potential of trastuzumab biosimilar CTP6

ASCO 2017: Round up

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer

Targeted sequencing in endocrine refractory breast cancer

Results from the APHINITY trial of two HER2 targeted agents with chemo